Low prevalence of late-onset neutropenia after rituximab treatment in patients with pemphigus - 09/11/20
Doi : 10.1016/j.jaad.2020.05.076
Katharina Boch, MD a, ⁎ 
, Detlef Zillikens, MD a, Ewan A. Langan, MD a, b, Enno Schmidt, MD, PhD a, c, Ralf J. Ludwig, MD c
, Detlef Zillikens, MD a, Ewan A. Langan, MD a, b, Enno Schmidt, MD, PhD a, c, Ralf J. Ludwig, MD c a Department of Dermatology and Center for Research on Inflammation of the Skin, University of Lübeck, Lübeck, Germany
b Dermatological Sciences, University of Manchester, Manchester, United Kingdom
c Lübeck Institute of Experimental Dermatology and Center for Research on Inflammation of the Skin, University of Lübeck, Lübeck, Germany
∗Correspondence and reprint requests to: Katharina Boch, MD, Department of Dermatology and Center for Research on Inflammation of the Skin, University of Lübeck, Ratzeburger Allee 160, 23538 Lübeck, GermanyDepartment of Dermatology and Center for Research on Inflammation of the SkinUniversity of LübeckRatzeburger Allee 160Lübeck23538Germany
| Funding sources: Excellence Cluster “Precision Medicine in Chronic Inflammation” (EXC 2167) from the Deutsche Forschungsgemeinschaft. |
|
| Conflicts of interest: None disclosed. |
|
| IRB approval status: Not applicable. |
© 2020
American Academy of Dermatology, Inc.. Publié par Elsevier Masson SAS. Tous droits réservés.
Vol 83 - N° 6
P. 1824-1825 - décembre 2020 Retour au numéro
Article précédent
- Factors associated with citation of original articles in 5 high-impact-factor dermatology journals
- Marius Mølsted Flege, Simon Francis Thomsen
- Factors impacting patient ratings of Mohs micrographic surgeons: Lessons gleaned from analysis of 17,527 online reviews
- Megan H. Trager, Courtney E. Ensslin, Weijia Fan, Faramarz H. Samie
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?